Validation Strategy for Ultrasensitive Mutation Detection

Marija Debeljak, Michael Noë, Stacy L. Riel, Lisa M. Haley, Alexis L. Norris, Derek A. Anderson, Emily M. Adams, Masaya Suenaga, Katie F. Beierl, Ming-Tseh Lin, Michael S Goggins, Christopher Gocke, James Eshleman

Research output: Contribution to journalArticle

Abstract

Background: Ultrasensitive detection of low-abundance DNA point mutations is a challenging molecular biology problem, because nearly identical mutant and wild-type molecules exhibit crosstalk. Reliable ultrasensitive point mutation detection will facilitate early detection of cancer and therapeutic monitoring of cancer patients. Objective: The objective of this study was to develop a method to correct errors in low-level cell line mixes. Materials and Methods: We tested sample mixes with digital-droplet PCR (ddPCR) and next-generation sequencing. Results: We introduced two corrections: baseline variant allele frequency (VAF) in the parental cell line was used to correct for copy number variation; and haplotype counting was used to correct errors in cell counting and pipetting. We found ddPCR to have better correlation for detecting low-level mutations without applying any correction (R2 = 0.80) and be more linear after introducing both corrections (R2 = 0.99). Conclusions: The VAF correction was found to be more significant than haplotype correction. It is imperative that various technologies be evaluated against each other and laboratories be provided with defined quality control samples for proficiency testing.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalMolecular Diagnosis and Therapy
DOIs
StateAccepted/In press - Jul 5 2018

Fingerprint

Point Mutation
Gene Frequency
Haplotypes
Cell Line
Polymerase Chain Reaction
Mutation
Physiologic Monitoring
Early Detection of Cancer
Quality Control
Molecular Biology
Technology
DNA
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Debeljak, M., Noë, M., Riel, S. L., Haley, L. M., Norris, A. L., Anderson, D. A., ... Eshleman, J. (Accepted/In press). Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 1-9. https://doi.org/10.1007/s40291-018-0350-z

Validation Strategy for Ultrasensitive Mutation Detection. / Debeljak, Marija; Noë, Michael; Riel, Stacy L.; Haley, Lisa M.; Norris, Alexis L.; Anderson, Derek A.; Adams, Emily M.; Suenaga, Masaya; Beierl, Katie F.; Lin, Ming-Tseh; Goggins, Michael S; Gocke, Christopher; Eshleman, James.

In: Molecular Diagnosis and Therapy, 05.07.2018, p. 1-9.

Research output: Contribution to journalArticle

Debeljak, M, Noë, M, Riel, SL, Haley, LM, Norris, AL, Anderson, DA, Adams, EM, Suenaga, M, Beierl, KF, Lin, M-T, Goggins, MS, Gocke, C & Eshleman, J 2018, 'Validation Strategy for Ultrasensitive Mutation Detection', Molecular Diagnosis and Therapy, pp. 1-9. https://doi.org/10.1007/s40291-018-0350-z
Debeljak M, Noë M, Riel SL, Haley LM, Norris AL, Anderson DA et al. Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy. 2018 Jul 5;1-9. https://doi.org/10.1007/s40291-018-0350-z
Debeljak, Marija ; Noë, Michael ; Riel, Stacy L. ; Haley, Lisa M. ; Norris, Alexis L. ; Anderson, Derek A. ; Adams, Emily M. ; Suenaga, Masaya ; Beierl, Katie F. ; Lin, Ming-Tseh ; Goggins, Michael S ; Gocke, Christopher ; Eshleman, James. / Validation Strategy for Ultrasensitive Mutation Detection. In: Molecular Diagnosis and Therapy. 2018 ; pp. 1-9.
@article{3d12beb20be5468881a713022e57486b,
title = "Validation Strategy for Ultrasensitive Mutation Detection",
abstract = "Background: Ultrasensitive detection of low-abundance DNA point mutations is a challenging molecular biology problem, because nearly identical mutant and wild-type molecules exhibit crosstalk. Reliable ultrasensitive point mutation detection will facilitate early detection of cancer and therapeutic monitoring of cancer patients. Objective: The objective of this study was to develop a method to correct errors in low-level cell line mixes. Materials and Methods: We tested sample mixes with digital-droplet PCR (ddPCR) and next-generation sequencing. Results: We introduced two corrections: baseline variant allele frequency (VAF) in the parental cell line was used to correct for copy number variation; and haplotype counting was used to correct errors in cell counting and pipetting. We found ddPCR to have better correlation for detecting low-level mutations without applying any correction (R2 = 0.80) and be more linear after introducing both corrections (R2 = 0.99). Conclusions: The VAF correction was found to be more significant than haplotype correction. It is imperative that various technologies be evaluated against each other and laboratories be provided with defined quality control samples for proficiency testing.",
author = "Marija Debeljak and Michael No{\"e} and Riel, {Stacy L.} and Haley, {Lisa M.} and Norris, {Alexis L.} and Anderson, {Derek A.} and Adams, {Emily M.} and Masaya Suenaga and Beierl, {Katie F.} and Ming-Tseh Lin and Goggins, {Michael S} and Christopher Gocke and James Eshleman",
year = "2018",
month = "7",
day = "5",
doi = "10.1007/s40291-018-0350-z",
language = "English (US)",
pages = "1--9",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Validation Strategy for Ultrasensitive Mutation Detection

AU - Debeljak, Marija

AU - Noë, Michael

AU - Riel, Stacy L.

AU - Haley, Lisa M.

AU - Norris, Alexis L.

AU - Anderson, Derek A.

AU - Adams, Emily M.

AU - Suenaga, Masaya

AU - Beierl, Katie F.

AU - Lin, Ming-Tseh

AU - Goggins, Michael S

AU - Gocke, Christopher

AU - Eshleman, James

PY - 2018/7/5

Y1 - 2018/7/5

N2 - Background: Ultrasensitive detection of low-abundance DNA point mutations is a challenging molecular biology problem, because nearly identical mutant and wild-type molecules exhibit crosstalk. Reliable ultrasensitive point mutation detection will facilitate early detection of cancer and therapeutic monitoring of cancer patients. Objective: The objective of this study was to develop a method to correct errors in low-level cell line mixes. Materials and Methods: We tested sample mixes with digital-droplet PCR (ddPCR) and next-generation sequencing. Results: We introduced two corrections: baseline variant allele frequency (VAF) in the parental cell line was used to correct for copy number variation; and haplotype counting was used to correct errors in cell counting and pipetting. We found ddPCR to have better correlation for detecting low-level mutations without applying any correction (R2 = 0.80) and be more linear after introducing both corrections (R2 = 0.99). Conclusions: The VAF correction was found to be more significant than haplotype correction. It is imperative that various technologies be evaluated against each other and laboratories be provided with defined quality control samples for proficiency testing.

AB - Background: Ultrasensitive detection of low-abundance DNA point mutations is a challenging molecular biology problem, because nearly identical mutant and wild-type molecules exhibit crosstalk. Reliable ultrasensitive point mutation detection will facilitate early detection of cancer and therapeutic monitoring of cancer patients. Objective: The objective of this study was to develop a method to correct errors in low-level cell line mixes. Materials and Methods: We tested sample mixes with digital-droplet PCR (ddPCR) and next-generation sequencing. Results: We introduced two corrections: baseline variant allele frequency (VAF) in the parental cell line was used to correct for copy number variation; and haplotype counting was used to correct errors in cell counting and pipetting. We found ddPCR to have better correlation for detecting low-level mutations without applying any correction (R2 = 0.80) and be more linear after introducing both corrections (R2 = 0.99). Conclusions: The VAF correction was found to be more significant than haplotype correction. It is imperative that various technologies be evaluated against each other and laboratories be provided with defined quality control samples for proficiency testing.

UR - http://www.scopus.com/inward/record.url?scp=85049579651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049579651&partnerID=8YFLogxK

U2 - 10.1007/s40291-018-0350-z

DO - 10.1007/s40291-018-0350-z

M3 - Article

SP - 1

EP - 9

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

ER -